Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.

Hormones & cancer - 1 Dec 2015

Barton Valerie N, D'Amato Nicholas C, Gordon Michael A, Christenson Jessica L, Elias Anthony, Richer Jennifer K

Abstract excerpt

Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) amplification. Due to the absence of these receptors, TNBC does not respond to traditional endocrine or HER2-targeted therapies that improve patient prognosis in other breast cancer subtypes. TNBC has a poor prognosis, and currently,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Receptor Antagonists
Share to Erb-b2 Receptor Tyrosine Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hormones

Share to Molecular Targeted Therapy

Share to Receptors, Androgen

Share to Receptors, Estrogen

Share to Receptors, Progesterone

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 26201402
DOI: 10.1007/s12672-015-0232-3
PMCID: PMC6897499

Genes

AR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.PMID 26201402Read ↗

Assessing the Androgen Receptor Status in Clinicopathologic and Hematologic Characteristics of the Triple-negative Breast CancerSemantic proximity Read ↗

Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication.Semantic proximity Read ↗

Prognostic value of androgen receptor expression and molecular alterations in metastatic triple-negative or low hormone receptor breast carcinomas.Semantic proximity Read ↗

Divide and Conquer—Targeted Therapy for Triple-Negative Breast CancerSemantic proximity Read ↗

[Androgen receptor-positive triple negative breast cancer: From biology to therapy].Semantic proximity Read ↗

Triple-negative breast cancer: unique biology and its management.Semantic proximity Read ↗

Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide <i>In Vivo</i>Semantic proximity Read ↗

Advances in the Understanding of the Pathogenesis of Triple-Negative Breast Cancer.Semantic proximity Read ↗

Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of researchSemantic proximity Read ↗

Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?Semantic proximity Read ↗

Triple-negative breast cancer and the need for new therapeutic targets.Semantic proximity Read ↗

Triple-negative breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.